###### Strengths and limitations of this study

-   Patients were recruited from multiple clinical settings, representing patients from different socioeconomic backgrounds.

-   One of the few studies to examine patients' informational needs following curative treatment for colorectal cancer, surveillance.

-   We used convenience sampling of attendees at a single meeting for the survey portion of the study.

-   The sample size for the stakeholder survey was small and exploratory in nature.

Background {#s1}
==========

Colorectal cancer (CRC) is the third leading cancer in men and women and the fourth most common cancer overall.[@R1] Nearly 80% of all newly diagnosed patients with CRC will be eligible for curative resection followed by post-treatment surveillance to detect recurrence and manage treatment associated effects.[@R3] Among those patients who develop recurrence, approximately one in three to four patients will be eligible for salvage surgery with curative intent.[@R4] Salvage surgery is associated with long-term survival of 30%--50%. However, not all patients will develop recurrence or be eligible for salvage resection, and it is estimated that between 15 and 50 patients undergo repeated surveillance testing to identify one patient eligible for salvage surgery.

Current guidelines for the frequency or duration of surveillance evaluation are variable, and there is uncertainty regarding the optimal timing, frequency, duration and modality of surveillance monitoring that should be conducted and for whom.[@R7] As a result, it is imperative that patients are active in their care and knowledgeable about CRC post-treatment surveillance and recurrence.

Prior studies have shown that survivors who have had curative resection for CRC have limited knowledge about surveillance testing and risks for recurrence.[@R8] However, these previous studies provide limited guidance about identifying different key facts survivors should understand so they can be active participants in decision making about CRC post-treatment surveillance planning or recurrence treatment. The purpose of this study was to identify patients' with CRC informational needs and elicit clinicians' and patient advocates' opinions regarding what patients should know about post-treatment surveillance to promote active participation in decisions about post-treatment surveillance.

Methods {#s2}
=======

Study design {#s2-1}
------------

This was a mixed-methods study consisting of semistructured, in-depth interviews with patients and a stakeholder survey with clinicians and patient advocates.

Patient and public involvement {#s2-2}
------------------------------

Patient advocates, clinicians, and researchers from the Alliance for Clinical Trials in Oncology were involved in all aspects of the study from development of the research question, outcome measures, study design, and data collection strategies during our biannual meetings. We presented the results to the stakeholders at an in-person meeting. Results were not shared with patient participants.

Study procedures {#s2-3}
----------------

### Patients {#s2-3-1}

Patients were recruited from two large academic cancer centres in the West and Southwest regions and one safety-net hospital in the Southwest region of the United States. Eligible patients were ≥18 years of age, 6 months to 5 years from curative resection of their colon or rectum, and were fluent in English. Researchers with no prior relationship with potential participants reviewed the upcoming surveillance appointments to identify eligible patients and assess interest in participating. After consent, the interviews were conducted either by phone or in-person by a male (VFR) with over 5 years of research experience with a Bachelors degree or a female (APH) research assistant with 2--3 years of research experience with a Bachelors degree. Both were trained by the first author to conduct the interviews. Interview participants knew the interviewers name and the purpose of the study. All interviews were conducted from September 2014 to July 2016, lasted about an hour, and were audio-recorded and transcribed verbatim. Transcripts were not returned to the participants for comment and/or corrections.

### Clinicians and patient advocates (stakeholders) {#s2-3-2}

Stakeholders who attended the Spring 2016 meeting of the Alliance for Clinical Trials in Oncology Network were eligible to participate. The stakeholders included gastrointestinal clinicians from academic and non-academic community-based practices and patient advocates. From here on out, the term 'advocates' refers to 'patient advocates'.

Data collection instruments and analysis {#s2-4}
----------------------------------------

### Semistructured interview guide and analysis {#s2-4-1}

The semistructured interview guide was developed by review of the literature and expert opinion and was iteratively refined during the data collection period. The final guide is available by request.

Framework method guided the thematic analysis.[@R9] Two or more researchers (LML, AC, GJC) coded all transcripts and met to discuss the coded transcripts. The coded texts were labelled with both deductive and inductive codes. The deductive codes were derived from the interview guide, and the inductive codes were developed iteratively. The coded texts were grouped together into themes and subthemes to describe the range of patient knowledge and attitudes regarding CRC surveillance. The coded text was rated on a dichotomous scale or a Likert scale ranging from low knowledge to high knowledge ([table 1](#T1){ref-type="table"}).

###### 

Patientknowledge coding framework

  Code                                                            Definition
  --------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stage of diagnosis                                              No: Does not accurately state the stage of diagnosis.Yes: Able to accurately state the stage of diagnosis.
  Site of diagnosis                                               No: Does not accurately state the site of diagnosis.Yes: Able to accurately state the site of diagnosis.
  How the cancer was detected                                     No: Unable to express how his or her cancer was detected.Yes: Able to express how his or her cancer was detected.
  Treatment modality and sequence                                 Low: Does not accurately describe or provide any details about how the cancer was detected.Medium: Provides more detail regarding treatments such as sequence and type of surgery or doses of chemotherapy.High: Provides correct facts about modality and sequence, uses the correct terms for treatment regimen (eg, can name the chemotherapy).
  Surveillance tests (eg, CEA, endoscopy, colonoscopy, imaging)   Low: Does not name the tests or names one test.Medium: Can list some tests (2/4).High: Knows most of the tests (3/4) or why they were being done.
  Harms of surveillance testing                                   Low: Is not able to list any harms of testing.Medium: Knows that risks exist but cannot explain or has poor understanding of the implications.High: Has realistic understanding/quantification of harms (eg, radiation exposure secondary cancer risk, but it is very low; false positives as a risk of over-surveillance).
  Frequency of surveillance tests                                 Low: Has no idea.Medium: Has some idea of testing frequency but is not communicated clearly/correctly.High: Differentiates the different timing between the tests.
  Duration of follow-up                                           Low: Has no idea.Medium: Has some concept of duration.High: Understands and can communicate duration; makes reference to appropriate timeline (eg, 5 years).
  Purpose of surveillance                                         Low: Unable to express the rationale for testing.Medium: Able to express to make sure cancer is not coming back.High: States that surveillance is to monitor for recurrence and toxicity for long-term effects, references quality of life, or life planning.
  Site of recurrence                                              Low: Believes that recurrence will be more likely to come back in the colon or has no idea where recurrence will occur.Medium: Believes that recurrence will occur somewhere other than the colon.High: Differentiates between distant and local recurrence, and/or able to describe that recurrence will likely occur in the liver or lungs.
  Sense of risk for recurrence                                    Low: Cannot describe or unsure of his or her risk for recurrence.Medium: Has a general sense of risk but lacks detail.High: Appropriately characterises his or her risk (eg, risk of recurrence can be different for people; distant is higher risk than local; earlier in post-treatment surveillance the risk is higher).
  Natural history of recurrence                                   Low: Does not understand how recurrence develops.Medium: Has a broad understanding of recurrence development.High: Shows understanding of recurrence development.
  Treatment options for recurrence                                Low: Is unable to describe or believes treatment for recurrence will be easy and straightforward or like what they had initially.Medium: Mentions some options for treatment of recurrence and/or states that treatment will be different from the treatment for their primary CRC.High: Understands that treatment will be difficult.
  Likelihood of cure                                              Low: Believes the likelihood of cure is high or has no idea.Medium: Knows that it may be harder to cure but lacks complete understanding.High: Knows that recurrence is very difficult to cure.

CEA, carcinoembrionic antigen; CRC, colorectal cancer.

The analysis also included comparing the themes and sub-themes across groups, such as comparing patients who were high versus low risk for recurrence based on stage of diagnosis and comparing patients from the different recruitment sites. Atlas.ti V.7 was used to facilitate analysis of the coded transcripts.

### Stakeholder survey {#s2-4-2}

Using the data from the qualitative interviews, we developed an anonymous survey to elicit stakeholders opinions regarding what patients should know about post-treatment surveillance. Additionally, candidate items were initially taken from published guidelines and expert opinion. The candidate list was reviewed by LML, AC and GJC for clarity, redundancy, and importance to determine the necessary facts and key messages to include in the survey. The survey asked stakeholders to indicate whether a fact or key message was necessary to make an informed decision about CRC surveillance by selecting agree, neutral, or disagree ([online supplementary file](#SP1){ref-type="supplementary-material"}). All survey data were collected anonymously, and we did not collect demographic information from the stakeholder survey participants. Analysis of the stakeholder surveys included counts and proportions.
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Results {#s3}
=======

Description of patients and stakeholders {#s3-1}
----------------------------------------

A total of 67 patients were contacted and 31 patients (46% response rate) were interviewed from three different medical centres ([table 2](#T2){ref-type="table"}). One patient was not included in the analysis because of a diagnosis of Lynch Syndrome. More than half of the patients were male (61%), and the majority were White (71%), non-Hispanic (90%) and married (71%). There was a good representation of educational levels with slightly more than half of individuals with less than a college education (52%). The majority of the patients were between 1 and 3 years post-treatment, had colon cancer and were diagnosed at stage III. The anonymous stakeholder survey was completed by 49 participants (38 clinicians and 11 patient advocates). The clinicians represented practising academic and community clinicians and the patient advocates represented individuals engaged in clinical cancer research.

###### 

Patient characteristics (n=31)

                                      n (%)
  ----------------------------------- -------------
  Age (median, IQR)                   60 (53--68)
  Gender                              
   Male                               19 (61.3)
   Female                             12 (38.7)
  Race                                
   White                              22 (71.0)
   Black                              5 (16.1)
   Other                              4 (12.9)
  Ethnicity                           
   Non-Hispanic                       28 (90.3)
   Hispanic                           3 (9.7)
  Education                           
   High school or less                10 (32.3)
   Some college/vocational training   6 (19.4)
   College                            10 (32.3)
   Advanced degree                    5 (16.1)
  Marital status                      
   Married                            22 (71.0)
   Not married                        9 (29.0)
  Time from surgery (months)          
   6--12                              5 (16.1)
   13--36                             20 (64.5)
   37--48                             6 (19.4)
  Tumour site                         
   Colon                              21 (67.7)
   Rectum                             10 (32.3)
  Stage at diagnosis                  
   Stage I                            3 (9.7)
   Stage II                           5 (16.1)
   Stage III                          23 (74.2)

Patients' knowledge of surveillance {#s3-2}
-----------------------------------

An overarching theme from the in-depth interviews was that patients had significant knowledge gaps regarding treatment, surveillance and recurrence ([table 3](#T3){ref-type="table"}). The overarching themes were consistent regardless of education level, marital status, or time since treatment. Patients generally had an accurate understanding of their stage at diagnosis (77%, 23/30) and site of cancer (85%, 22/26) based on their personal experience. However, there were patients who were confused about their stage and didn't completely grasp the difference between cancer in the colon or rectum.

###### 

Patient knowledge of post-treatment colorectal cancer surveillance and recurrence

  ----------------------------------------------------------------------------------------------------------
                                     Mentioned\   Quality of expressed knowledge\*               
                                     n (%)                                                       
  ---------------------------------- ------------ ---------------------------------- ----------- -----------
  Treatment modality and sequence    31 (100.0)   1 (3.2)                            23 (74.2)   7 (22.6)

  Types of surveillance tests        30 (96.8)    5 (16.7)                           14 (46.7)   11 (36.7)

  Frequency of surveillance tests    31 (100.0)   8 (25.9)                           21 (67.7)   2 (6.5)

  Harms of surveillance testing      21 (67.7)    9 (29.0)                           11 (52.4)   1 (4.8)

  Duration of surveillance           24 (77.4)    10 (41.7)                          7 (29.2)    7 (29.2)

  Purpose of surveillance            31 (100.0)   5 (16.1)                           20 (64.5)   6 (19.4)

  Site of recurrence                 27 (87.1)    20 (74.1)                          4 (14.8)    3 (11.1)

  Sense of risk for recurrence       24 (77.4)    16 (66.7)                          5 (20.1)    3 (12.5)

  Natural history of recurrence      19 (61.3)    14 (73.1)                          4 (21.1)    1 (5.3)

  Treatment options for recurrence   26 (83.9)    21 (80.1)                          5 (19.2)    0 (0.0)

  Likelihood of cure                 24 (77.4)    15 (62.5)                          8 (33.3)    1 (4.2)
  ----------------------------------------------------------------------------------------------------------

\*The quality of expressed knowledge is based on the denominator of those mentioning the knowledge element.

> Interviewer: It was colorectal, so was it in your rectum or what---or was it?
>
> Patient: Yeah, I guess. I guess you\'d say that
>
> Interviewer: Okay. Your colon?
>
> Patient: They had me with a---you know---a ostomy---a colostomy bag (Patient 31)

Overall, despite a desire to monitor for recurrence, patients had an incomplete understanding of recurrence mechanism, site, natural history and potential for cure ([table 3](#T3){ref-type="table"}). Very few patients could define cancer recurrence or describe where and when recurrence was most likely to occur. They described recurrence as '*cancer coming back---Patient 03*' and a minority of patients could state that recurrence was most likely to occur in the lungs or liver. Few understood the limited potential for cure after recurrence, which was demonstrated by the belief that the treatment for recurrence would be the same as the treatment for the primary cancer: "*I think pretty much probably the same, chemo and surgery, maybe radiation---Patient 04*". Many confused recurrence with a new primary colon cancer (*"Because you can have cancer further up---Patient 05*"). Patients commonly believed that if recurrence was found early, there was a higher likelihood for cure; this concept may have been influenced by broader concepts of CRC screening and early detection of primary disease. For instance, one patient's description of the purpose of surveillance demonstrates the inability to differentiate screening and early detection of primary disease and surveillance for detection of recurrence, which is compounded by the belief that recurrence of cancer can be prevented. *"To make sure \[...\] that nothing has changed in the body \[...\] this time they found polyps \[...\] It's also preventative. -- Patient 05".*

Patients had little understanding of the concept of post-treatment surveillance ([table 3](#T3){ref-type="table"}). They were able to broadly list the tests involved and general frequency of these tests, but it was from their experience and not from a deeper understanding of the reasons for the tests or the rationale for testing frequency or duration. Additionally, patients did not seem to think there were specific harms to surveillance testing, or they mentioned harms in passing. For example, one patient mentioned radiation as a possible harm but of minimal concern. Concern for false positive test results and possible need for additional testing also did not arise.

Patients equated the term surveillance with 'follow-up', but in general lacked a granular understanding of the purpose of surveillance and its implications for survival. However, one patient differentiated between 'surveillance' and 'follow-up'. For this patient, 'surveillance' was clearly about detecting recurrence: *"Okay. So, in my mind, surveillance is looking for a recurrence or a metastasis. Like the scans I consider surveillance. The CEA level I consider surveillance. The colonoscopy and the sigmoidoscopy I consider surveillance.---Patient 21"*.

The concept of 'follow-up' was about maintaining quality of life:

> And then follow-up care---I mean since I had my ileostomy reversal in \[date\]---I mean I'm not sure how familiar you are with---you know---kind of how that goes and what the healing is like, but I feel like it was a really long haul and it's been almost more difficult than having chemo. It's kind of getting back to like regular bowel function. So, I was seeing---and this is where I've gotten my just kind of follow-up care that's not surveillance, but I had visits with a nutritionist I had visits with another nurse in my surgeon's practice. I had visits with a pelvic floor physical therapist. -- Patient 21

Although some patients stated they were going to be followed for 5 years, they had little to no understanding of the rationale for the follow-up time window. For those who were not able to express the 5-year duration, they expressed a belief that they would always be followed. For example one patient said "*I always expect to be---you know---checked up on once in a while. You know? Just to make sure it didn't come back. -- Patient 06*".

Stakeholder opinions regarding information patients should know about CRC surveillance {#s3-3}
--------------------------------------------------------------------------------------

Advocates and clinicians agreed that slightly half of the topics (six out of 13 topics) were important for patients to know: duration and frequency of surveillance, tests used for surveillance, the purpose of surveillance, timing of recurrence, definition of recurrence and basic CRC facts ([figure 1](#F1){ref-type="fig"}). There was disagreement on four of these topics.

![Comparing stakeholder responses this figure presents the stakeholder responses to what they feel patients should know about surveillance following curative resection of their colon or rectum. The values presented are in percentages. GI, gastrointestinal.](bmjopen-2018-025888f01){#F1}

More advocates agreed that patients should know site of recurrence (90% of advocates vs 65% of clinicians), the treatment options for recurrence (100% of advocates vs 58% of clinicians), goals of treatment (eg, curative or palliative) for recurrence (100% of advocates vs 38% clinicians), and potential harms of surveillance testing (100% vs 68%) compared with clinicians. Compared with clinicians, somewhat fewer advocates agreed that patients should know the impact of surveillance on survival (55% of advocates vs 70% of clinicians) and situations where surveillance may not be beneficial, such as advanced age (55% of advocates vs 76% of clinicians).

Discussion {#s4}
==========

This exploratory study highlights areas for consideration regarding patients' informational needs and stakeholders' opinions regarding what patients should understand about surveillance and recurrence in order to make informed choices for their care. The in-depth interviews suggested that patients understood their diagnosis and treatment, but had significant knowledge gaps regarding recurrence and the purpose of post-treatment surveillance. The stakeholder survey suggested that advocates and clinicians differed in their opinions of what patients should know about surveillance and recurrence.

Patients' misperceptions about surveillance and recurrence is an important barrier for active participation in their care.[@R10] The in-depth interviews suggested that patients do not have sufficient knowledge to actively participate in their post-treatment care; however, they did have a broad understanding of their diagnosis and treatment. Salz and colleagues found that most survivors of CRC remembered information about their treatment, but had a poor grasp on their risk of local recurrence, distant recurrence, or developing a new primary CRC.[@R8] In our study, we found that patients did not understand the purpose of the different surveillance tests, the underlying rationale for the different timing of tests, the duration of surveillance, the natural history of recurrence and the likelihood of cure for recurrence. Our findings are similar to those of a study conducted with African American survivors of CRC, which revealed poor understanding of post-treatment surveillance testing and uncertainty about when they would be considered cured or no longer at significant risk for recurrence.[@R11] The findings from this exploratory study suggests that these knowledge gaps are present regardless of education level, marital status, and time since treatment. Thus, clinicians need effective strategies to better educate patients about CRC surveillance.

Patients' misunderstanding of CRC surveillance could be problematic for clinicians as well. Fear of recurrence is one of the most important concerns among survivors of cancer.[@R12] They can experience significant anxiety about the risk for recurrence, which can be out of proportion to their actual risk and look to their clinicians to alleviate this anxiety, often with the expectation of evaluating their cancer status with a test. Clinicians may have a difficult time explaining to patients the indications and limitations of testing, the appropriate frequency, or why their visits are becoming less frequent and will eventually end after 5 years, especially for patients who have a high fear of recurrence and are hesitant to separate from their oncology clinicians.[@R13] In the event of recurrence, clinicians will have to explain that treatment for recurrence is likely to be more difficult. However, this reality could influence patients' underlying desire for testing. These very difficult and potentially time-consuming conversations require communication of difficult concepts with careful attention to use of plain language.[@R14]

From our stakeholder surveys, there was disagreement between advocates and clinicians regarding what facts or key messages need to be discussed. Our results confirm prior reports of this disconnect and highlight the importance of patient-centred care.[@R13] Since not all patients who are identified with cancer recurrence will be eligible for curative-intent treatment, the role of intensive surveillance testing in such patients can be debated. However, compared with clinicians, fewer advocates felt that patients should know about contraindications to surveillance, or the potential for limited impact of surveillance on survival. These findings may reflect a belief that everyone has the right to receipt of care, even when treatment may not be beneficial, and that patients must continue to fight cancer by monitoring its recurrence. The data may also underpin patients' unwillingness to consider situations of medical futility in patients who might be too frail to undergo salvage surgery. Far fewer clinicians agreed that patients should know the potential harms of surveillance tests, recurrence treatment outcomes, potential treatments for recurrence, sites where recurrence could occur, and risk of recurrence. These results may suggest that clinicians are hesitant to get into specifics about recurrence, preferring to focus on the patient being 'cancer free' for now. This idea is consistent with the results of a study analysing patients and clinicians for post-treatment surveillance of pancreatic cancer, a disease where few options exist for treatment should recurrence be identified.[@R13] It could also reflect clinicians' difficulty with providing individualised information on prognosis while still providing hope.[@R17]

A limitation of this study is the small sample size; however, thematic saturation was reached within 10--15 interviews regarding patients' expressed knowledge and new thematic insights are unlikely to be achieved simply by interviewing more patients. The sample was also diverse with respect to education level and included patients from a safety-net hospital. Another potential limitation is the effect of the interviewer on the participants' responses. Strategies were implemented to minimise the impact of the interviewers on the participants, such as, asking open ended questions, avoiding leading questions and not offering an opinion when queried. The generalisability of the results from the stakeholder survey is limited because the clinicians and advocates are highly engaged in research as part of their involvement in the National Cancer Institute Community Oncology Research Program. The advocates may not represent patients and caregivers at large as they are more engaged and knowledgeable about post-treatment surveillance for cancer. Since the survey was anonymous, we did not collect any additional demographic information from the clinicians nor patient advocates. The response rate could not be determined because the anonymous survey was distributed to attendees to the Gastrointestinal Committee and Patient Advocate Committee meetings which included individuals who may not have been clinicians nor patient advocates.

In summary, the findings from this exploratory study suggests patients have a significant knowledge gap regarding post-treatment surveillance and recurrence. There is a strong belief among advocates that clinicians should attempt to help their patients to be more informed about their disease and associated treatments. Patients need educational interventions to address these gaps to be more active in their care. A prior study found that survivors of cancer were unsatisfied with the available cancer information and that the need for cancer information decreased over time, but only among women.[@R19] This latter study included individuals who were beyond the 5-year post-treatment surveillance period; thereby, limiting this findings relevance for patients during the post-treatment surveillance period. A more recent study with patients found that the need for information declined over time.[@R20] Clinicians would also benefit from interventions to promote conversations about post-treatment surveillance of CRC that more closely align with the information needs of patients. One promising approach is educational interventions combined with communication skills training for clinicians. The communication skills training could focus on scaffolding clinicians' ability to share information that is responsive to each patients' desire and need for information, for example, how much. This approach recognises that patients differ in the amount of information they want. For instance, some patients want as much information as possible and others may be overwhelmed by too much information.[@R21] Such interventions could help patients and clinicians be clear about the goals of care during post-treatment surveillance and recurrence, resulting in more patient-centred care.
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